# Solidion Technology Inc.: financial statements, quarterly

STI · Nasdaq · CIK 1881551 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sti.md) · [Financials](/companies/sti/financials.md) · [Filings](/companies/sti/filings.md) · [Insiders](/companies/sti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001213900-24-100243.md) | [0.0 d](/filings/0001213900-25-032301.md) | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-086220.md) | [0.0](/filings/0001213900-25-112830.md) | [0.0 d](/filings/0001213900-26-044126.md) | [0.1](/filings/0001213900-26-059602.md) | [0.1](/filings/0001213900-26-086220.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-086220.md) | [0.0](/filings/0001213900-25-112830.md) | [0.0 d](/filings/0001213900-26-044126.md) | [0.0](/filings/0001213900-26-059602.md) | [0.0 d](/filings/0001213900-26-086220.md) |
| Gross profit | $m | [0.0](/filings/0001213900-24-100243.md) | [0.0 d](/filings/0001213900-25-032301.md) | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-086220.md) | [0.0](/filings/0001213900-25-112830.md) | [0.0 d](/filings/0001213900-26-044126.md) | [0.1](/filings/0001213900-26-059602.md) | [0.1](/filings/0001213900-26-086220.md) |
| Research and development | $m | [0.9](/filings/0001213900-24-100243.md) | [0.7 d](/filings/0001213900-25-032301.md) | [0.7](/filings/0001213900-25-046069.md) | [0.4](/filings/0001213900-25-112742.md) | [0.5](/filings/0001213900-25-112830.md) | [0.8 d](/filings/0001213900-26-044126.md) | [1.4](/filings/0001213900-26-059602.md) | [0.4](/filings/0001213900-26-086220.md) | [0.5](/filings/0001213900-25-112830.md) | [1.1 d](/filings/0001213900-26-044126.md) | [0.4](/filings/0001213900-26-059602.md) | [0.4](/filings/0001213900-26-086220.md) |
| Selling, general and administrative | $m | [0.6](/filings/0001213900-24-100243.md) | [0.4 d](/filings/0001213900-25-032301.md) | [3.0](/filings/0001213900-25-046069.md) | [2.5](/filings/0001213900-25-112742.md) | [3.7](/filings/0001213900-25-112830.md) | [1.6 d](/filings/0001213900-26-044126.md) | [1.8](/filings/0001213900-26-059602.md) | [1.4](/filings/0001213900-26-086220.md) | [1.2](/filings/0001213900-25-112830.md) | [5.1 d](/filings/0001213900-26-044126.md) | [1.5](/filings/0001213900-26-059602.md) | [1.1](/filings/0001213900-26-086220.md) |
| Operating income | $m | [(1.4)](/filings/0001213900-24-100243.md) | [(1.1) d](/filings/0001213900-25-032301.md) | [(3.8)](/filings/0001213900-25-046069.md) | [(2.9)](/filings/0001213900-25-112742.md) | [(4.2)](/filings/0001213900-25-112830.md) | [(2.4) d](/filings/0001213900-26-044126.md) | [(3.1)](/filings/0001213900-26-059602.md) | [(1.8)](/filings/0001213900-26-086220.md) | [(1.7)](/filings/0001213900-25-112830.md) | [(6.3) d](/filings/0001213900-26-044126.md) | [(1.8)](/filings/0001213900-26-059602.md) | [(1.4)](/filings/0001213900-26-086220.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0001213900-24-050479.md) | [0.0](/filings/0001213900-26-044126.md) | [0.0](/filings/0001213900-26-044126.md) | [0.3 d](/filings/0001213900-26-044126.md) | [0.1](/filings/0001213900-26-059602.md) | [0.1](/filings/0001213900-26-086220.md) | [0.1](/filings/0001213900-25-112830.md) | [(0.2) d](/filings/0001213900-26-044126.md) | [0.1](/filings/0001213900-26-059602.md) | [0.2](/filings/0001213900-26-086220.md) |
| Income tax | $m | [0.0](/filings/0001213900-24-100243.md) | not reported | [0.0](/filings/0001213900-24-050479.md) | [0.0](/filings/0001213900-24-067911.md) | [0.0](/filings/0001213900-24-100243.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(1.4)](/filings/0001213900-24-100243.md) | [(1.1) d](/filings/0001213900-25-032301.md) | [(32.5)](/filings/0001213900-26-044126.md) | [21.9](/filings/0001213900-26-044126.md) | [(9.7)](/filings/0001213900-26-044126.md) | [(12.1) d](/filings/0001213900-26-044126.md) | [9.2](/filings/0001213900-26-086220.md) | [(2.1)](/filings/0001213900-26-086220.md) | [(4.1)](/filings/0001213900-25-112830.md) | [(44.0) d](/filings/0001213900-26-044126.md) | [(1.4)](/filings/0001213900-26-086220.md) | [(2.9)](/filings/0001213900-26-086220.md) |
| Diluted EPS | $ per share | not reported | not reported | [(20.48)](/filings/0001213900-26-044126.md) | [5.01](/filings/0001213900-26-044126.md) | [(4.41)](/filings/0001213900-26-044126.md) | not reported | [(0.30)](/filings/0001213900-26-059602.md) | [(0.70)](/filings/0001213900-26-086220.md) | [(1.33)](/filings/0001213900-25-112830.md) | not reported | [(0.18)](/filings/0001213900-26-059602.md) | [(0.35)](/filings/0001213900-26-086220.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001213900-24-100243.md) | not reported | [(20.48)](/filings/0001213900-26-044126.md) | [11.92](/filings/0001213900-26-044126.md) | [(4.41)](/filings/0001213900-26-044126.md) | not reported | [3.06](/filings/0001213900-26-059602.md) | [(0.70)](/filings/0001213900-26-086220.md) | [(1.33)](/filings/0001213900-25-112830.md) | not reported | [(0.18)](/filings/0001213900-26-059602.md) | [(0.35)](/filings/0001213900-26-086220.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001213900-23-087427.md) | not reported | not reported | not reported | not reported | [3.4](/filings/0001213900-26-044126.md) | [1.2](/filings/0001213900-25-046069.md) | [0.1](/filings/0001213900-25-112742.md) | [0.2](/filings/0001213900-25-112830.md) | [0.2](/filings/0001213900-26-044126.md) | [0.0](/filings/0001213900-26-059602.md) | [27.7](/filings/0001213900-26-086220.md) |
| Current assets | $m | [0.1](/filings/0001213900-23-087427.md) | [0.3](/filings/0001213900-25-032301.md) | [3.5](/filings/0001213900-24-050479.md) | [1.6](/filings/0001213900-24-067911.md) | [2.0](/filings/0001213900-24-100243.md) | [3.9](/filings/0001213900-26-044126.md) | [2.6](/filings/0001213900-25-046069.md) | [1.2](/filings/0001213900-25-112742.md) | [1.0](/filings/0001213900-25-112830.md) | [0.8](/filings/0001213900-26-086220.md) | [1.4](/filings/0001213900-26-059602.md) | [28.4](/filings/0001213900-26-086220.md) |
| Total assets | $m | [42.6](/filings/0001213900-23-087427.md) | [4.4](/filings/0001213900-25-032301.md) | [8.5](/filings/0001213900-24-050479.md) | [6.5](/filings/0001213900-24-067911.md) | [6.1](/filings/0001213900-24-100243.md) | [8.0](/filings/0001213900-26-044126.md) | [6.7](/filings/0001213900-25-046069.md) | [5.3](/filings/0001213900-25-112742.md) | [5.1](/filings/0001213900-25-112830.md) | [4.8](/filings/0001213900-26-086220.md) | [5.3](/filings/0001213900-26-059602.md) | [32.4](/filings/0001213900-26-086220.md) |
| Current liabilities | $m | [4.3](/filings/0001213900-23-087427.md) | not reported | not reported | not reported | not reported | not reported | not reported | [19.4](/filings/0001213900-25-112742.md) | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [8.6](/filings/0001213900-23-087427.md) | [1.0](/filings/0001213900-25-032301.md) | [49.1](/filings/0001213900-24-050479.md) | [24.7](/filings/0001213900-24-067911.md) | [24.9](/filings/0001213900-24-100243.md) | [30.9](/filings/0001213900-26-044126.md) | [18.8](/filings/0001213900-25-046069.md) | [19.4](/filings/0001213900-25-112742.md) | [22.5](/filings/0001213900-25-112830.md) | [12.0](/filings/0001213900-26-086220.md) | [13.6](/filings/0001213900-26-059602.md) | [10.7](/filings/0001213900-26-086220.md) |
| Shareholders' equity | $m | [3.7](/filings/0001213900-24-100243.md) | [3.4](/filings/0001213900-26-044126.md) | [(40.6)](/filings/0001213900-26-044126.md) | [(18.2)](/filings/0001213900-26-044126.md) | [(18.8)](/filings/0001213900-26-044126.md) | [(22.9)](/filings/0001213900-26-086220.md) | [(12.2)](/filings/0001213900-26-086220.md) | [(14.1)](/filings/0001213900-26-086220.md) | [(17.4)](/filings/0001213900-25-112830.md) | [(7.2)](/filings/0001213900-26-086220.md) | [(8.3)](/filings/0001213900-26-086220.md) | [21.7](/filings/0001213900-26-086220.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,149) d](/filings/0001213900-24-100243.md) | [(769) d](/filings/0001213900-25-032301.md) | [(2,041)](/filings/0001213900-25-046069.md) | [(1,501) d](/filings/0001213900-25-112742.md) | [(2,136) d](/filings/0001213900-25-112830.md) | [(1,701) d](/filings/0001213900-26-044126.md) | [(2,342)](/filings/0001213900-26-059602.md) | [(914) d](/filings/0001213900-26-086220.md) | [(352) d](/filings/0001213900-25-112830.md) | [(929) d](/filings/0001213900-26-044126.md) | [(142)](/filings/0001213900-26-059602.md) | [(3,973) d](/filings/0001213900-26-086220.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001213900-25-112830.md) | [0.0 d](/filings/0001213900-26-044126.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.2](/filings/0001213900-22-029026.md) | [69.8](/filings/0001213900-24-050479.md) | [69.8](/filings/0001213900-24-067911.md) | [1.6](/filings/0001213900-26-044126.md) | [2.0](/filings/0001213900-26-044126.md) | [2.2](/filings/0001213900-26-044126.md) | [3.0](/filings/0001213900-26-059602.md) | [3.0](/filings/0001213900-26-086220.md) | [3.1](/filings/0001213900-25-112830.md) | [7.8](/filings/0001213900-26-059602.md) | [8.4](/filings/0001213900-26-086220.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,512,771 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001213900-26-086220.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.